TickerGuard
Buy Day today: Good (63) Broad market participation · no major macro event
OABI

OmniAb Inc.

Healthcare · Biotechnology

4.30$ +0.7% vs. previous close Closing price · As of: Aug 21, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of OmniAb Inc. (OABI). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — OABI
Segment Q1 2025 Q2 2025 Q1 2026 Q2 2026
Reportable Segment $4.2M 100.0% $3.9M 100.0% $14.4M 100.0% $13.4M 100.0%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Revenue by product line

Revenue by product line — OABI
Segment Q1 2025 Q2 2025 Q1 2026 Q2 2026
License and milestone revenue $2.0M 48.7% $1.2M 31.9% $12.0M 83.4% $9.5M 70.9%
Service revenue $1.9M 45.8% $1.9M 49.7% $2.1M 14.6% $2.5M 18.4%
xPloration revenue $42.0K 1.0% $608.0K 15.6% $54.0K 0.4% $1.2M 8.7%
Royalty revenue $188.0K 4.5% $111.0K 2.8% $241.0K 1.7% $266.0K 2.0%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?